Early phase II trial of human rotavirus vaccine candidate RV3.
A naturally attenuated, human neonatal strain, rotavirus vaccine candidate RV3, was tested in a limited phase II randomized double-blind controlled trial. Doses of 1 ml, containing placebo or 6.5 x 10(5) fluorescent cell forming units (fcfu) of virus in AGMK cells, were given at 3, 5 and 7 months of age. Limited replication in the small intestine is implied by the lack of virus excretion, and by the occurrence of an immune response in only 46% of the infants. However, those who developed an immune response were partially protected against rotavirus disease during the subsequent winter epidemic (protective efficacy 54%), supporting observations of protection induced by natural infection by this strain. Protection appeared to be heterotypic. Further trials are warranted, employing strategies to increase immunogenicity of this human rotavirus candidate vaccine.
Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Melbourne, Vic. 3052, Australia. bernesg@cryptic.rch.unimelb.edu.au
Graeme L
GL
Barnes
Jennifer S
JS
Lund
Susan V
SV
Mitchell
Leonie
L
De Bruyn
Leone
L
Piggford
Arnold L
AL
Smith
Janine
J
Furmedge
Paul J
PJ
Masendycz
Helen C
HC
Bugg
Nada
N
Bogdanovic-Sakran
John B
JB
Carlin
Ruth F
RF
Bishop
D000914:Antibodies, Viral / Q000097:blood; D004311:Double-Blind Method; D004361:Drug Tolerance; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D007421:Intestine, Small / Q000821:virology; D012401:Rotavirus / Q000276:immunology / Q000302:isolation & purification / Q000502:physiology; D012400:Rotavirus Infections / Q000276:immunology / Q000517:prevention & control; D022243:Rotavirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology*; D012449:Safety; D014779:Virus Replication
D000914:Antibodies, Viral; D022243:Rotavirus Vaccines